Susie Bullock

Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

Raffit Hassan, Susie Bullock, Ahalya Premkumar et al. · Clinical Cancer Research · 2007 · 381 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network

Nicholas J. Robert, Janet L. Espirito, Liwei Chen et al. · Lung Cancer · 2022 · 80 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.

Nicholas J. Robert, Esmond Nwokeji, Janet L. Espirito et al. · Journal of Clinical Oncology · 2021 · 53 citations

Medicine, Oncology, Molecular Diagnostics +14

Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial

David R. Fogelman, Mehrdad Jafari, Gauri R. Varadhachary et al. · Cancer Chemotherapy and Pharmacology · 2011 · 24 citations

Medicine, Oncology, Pharmacology +16